scholarly journals Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections

2021 ◽  
pp. 1-4
Author(s):  
Moeed Ahmed ◽  
Neil Alouch ◽  
Arslan Ahmed ◽  
Sunil K. Jagadesh
Keyword(s):  
Renal Function ◽  
Intravitreal Bevacizumab ◽  
Uncontrolled Hypertension

scholarly journals Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry

2019 ◽  
Vol 40 (42) ◽  
pp. 3474-3482 ◽  
Author(s):  
Felix Mahfoud ◽  
Michael Böhm ◽  
Roland Schmieder ◽  
Krzysztof Narkiewicz ◽  
Sebastian Ewen ◽  
...  
Keyword(s):  
Renal Function ◽  
Real World ◽  
Active Sites ◽  
Renal Denervation ◽  
Uncontrolled Hypertension ◽  
Open Label ◽  
Hypertensive Patients ◽  
Safety And Efficacy

Abstract Aims Several studies and registries have demonstrated sustained reductions in blood pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in real-world patients with uncontrolled hypertension, however, remains unknown. The objective of this study was to assess the long-term safety and efficacy of RDN, including its effects on renal function. Methods and results The Global SYMPLICITY Registry is a prospective, open-label registry conducted at 196 active sites worldwide in hypertensive patients receiving RDN treatment. Among 2237 patients enrolled and treated with the SYMPLICITY Flex catheter, 1742 were eligible for follow-up at 3 years. Baseline office and 24-h ambulatory systolic BP (SBP) were 166 ± 25 and 154 ± 18 mmHg, respectively. SBP reduction after RDN was sustained over 3 years, including decreases in both office (−16.5 ± 28.6 mmHg, P < 0.001) and 24-h ambulatory SBP (−8.0 ± 20.0 mmHg; P < 0.001). Twenty-one percent of patients had a baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Between baseline and 3 years, renal function declined by 7.1 mL/min/1.73 m2 in patients without chronic kidney disease (CKD; eGFR ≥60 mL/min/1.73 m2; baseline eGFR 87 ± 17 mL/min/1.73 m2) and by 3.7 mL/min/1.73 m2 in patients with CKD (eGFR <60 mL/min/1.73 m2; baseline eGFR 47 ± 11 mL/min/1.73 m2). No long-term safety concerns were observed following the RDN procedure. Conclusion Long-term data from the Global SYMPLICITY Registry representing the largest available cohort of hypertensive patients receiving RDN in a real-world clinical setting demonstrate both the safety and efficacy of the procedure with significant and sustained office and ambulatory BP reductions out to 3 years.

Increased Cyclosporine Blood Concentrations Due to Verapamil Administration

1988 ◽  
Vol 22 (9) ◽  
pp. 705-707 ◽  
Author(s):  
Thomas G. Maggio ◽  
David W. Bartels
Keyword(s):  
Renal Function ◽  
Calcium Channel ◽  
Immunosuppressive Agent ◽  
Uncontrolled Hypertension ◽  
Blood Concentrations ◽  
Blocking Agents ◽  
Calcium Channel Blocking Agents ◽  
Channel Blocking ◽  
Transplanted Organs ◽  
Nephroprotective Effect

Cyclosporine is an immunosuppressive agent used to prevent rejection of transplanted organs. Monitoring cyclosporine blood concentrations is important to ensure adequate levels to prevent graft rejection while minimizing the risk of toxicity. A 45-year-old man who received a kidney transplant seven months previously is described. He had been receiving cyclosporine along with azathioprine and prednisone for immunosuppression since the transplant. His cyclosporine blood concentrations and renal function were stable during this time. Due to uncontrolled hypertension, sustained-release (SR) verapamil 240 mg/d was added with no change in cyclosporine levels. However, after increasing the dose of verapamil SR to 360 mg/d a dramatic increase in cyclosporine concentrations occurred. His renal function remained stable during this time. The interaction between cyclosporine and the calcium-channel blocking agents along with a possible nephroprotective effect of the calcium-channel blocking agents when used with cyclosporine are discussed.

scholarly journals EFFECT OF RENAL DENERVATION ON RENAL FUNCTION OF PATIENTS WITH UNCONTROLLED HYPERTENSION: INSIGHTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED, SHAM-CONTROLLED TRIALS

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e290-e291
Author(s):  
Konstantinos Stavropoulos ◽  
Alexandra Katsimardou ◽  
Dimitrios Patoulias ◽  
Konstantinos Imprialos ◽  
Sofia Bouloukou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Function ◽  
Renal Denervation ◽  
Meta Analysis ◽  
Uncontrolled Hypertension ◽  
Controlled Trials

scholarly journals Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study

2018 ◽  
Vol 7 ◽  
pp. e1299
Author(s):  
Sina Bagheri ◽  
Banafshe Dormanesh ◽  
Mehrdad Afarid ◽  
Mohammad Mahdi Sagheb
Keyword(s):  
Renal Function ◽  
Diabetic Nephropathy ◽  
Observational Study ◽  
Renal Dysfunction ◽  
Intravitreal Injection ◽  
Prospective Observational Study ◽  
Microvascular Complications ◽  
Systemic Exposure ◽  
Intravitreal Bevacizumab ◽  
Vegf Level

Background: Proliferative diabetic retinopathy (PDR) is one of the most important microvascular complications among the patients with diabetes. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent enacts a key role in PDR. Some studies have dealt with the systemic exposure to these agents after intravitreal administration. However, renal dysfunction following this therapy has scarcely been reported. Hence, this study aimed to determine the effect of intravitreal bevacizumab treatment on the deterioration of renal function and proteinuria.Materials and Methods: This present prospective observational study was performed on 40 patients with diabetic nephropathy and PDR and/or significant diabetic macular edema as the candidates for receiving intravitreal injection of bevacizumab. To evaluate renal function, changes in the urinary albumin-to-creatinine ratio (UACR), serum creatinine (SCr), and estimated glomerular filtration rate (eGFR) one month after injection were measured. Also, changes in systolic and diastolic blood pressures (BPs), plasma VEGF level, platelet, white blood cell (WBC) counts, and hemoglobin (Hb) level were measured at the baseline and one month after treatment.Results: The mean age of the patients was 60.3 ± 9.2 years, and 33 patients were female. The decrease in the plasma VEGF level and platelet count, as well as the increase in diastolic BP, and Hb level were significant. However, systolic BP and WBC count remained unchanged. There were no significant changes in UACR, SCr, and eGFR after the injection as compared to baseline (P>0.05).Conclusion: Our study indicated that intravitreal bevacizumab injection was not associated with renal dysfunction and proteinuria in patients with diabetic nephropathy. Nevertheless, diastolic BP and Hb level could increase after one month. [GMJ.2018;In press:e1299]

P3570Bilateral renal artery stenting is effective method for the treatment of uncontrolled hypertension and renal function

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J Uzokov ◽  
A L Alyavi ◽  
B A Alyavi ◽  
S A Iskhakov ◽  
D D Payziev
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Serum Creatinine ◽  
Renal Artery ◽  
Uncontrolled Hypertension ◽  
Renal Artery Stenting ◽  
Group I ◽  
Group Ii ◽  
Bilateral Stenting

Abstract Background Renal artery (RA) stenosis is one of the main causes of severe uncontrolled primary hypertension among population. Aim of the study was to investigate effectiveness of stent replacement in renal arteries and influence it on renal function in uncontrolled hypertensive patients (UHP) with pharmacotherapies. Methods 86 consecutive UHP with renal etiology confirmed by angiography were enrolled in this study. Mean age of the patients was 43.2±12.5 years (aged 31–59 years, male=46%). Blood pressure, serum creatinine, microalbuminuria were assessed at baseline and after the intervention and during the follow-up for statistics. Mean follow-up was 2.0±1.0 years. Results Total of 128 hemodynamically significant renal artery stenosis were treated by implanting stents in all 86 patients. Among them in 42 patients were performed bilateral stenting (Group I) and 44 patients unilateral stenting (Group II). Systolic and diastolic blood pressure (SBP, DBP) decreased in both groups during the follow-up, however it was noted that only SBP were decreased significantly in Group I (unilateral stenting) whilst reduction in DBP not significantly when compared to Group II. Mean reduction in SBP was from 165.0±20.5 mmHg to 130.4±14.0 mmHg in Group I vs. from 158.0±22.0 to 135.0±15.0 mmHg in Group II (P=0.003 when compared two groups) and in DBP was from 95.0±11.2 mmHg to 83.4±8.0 mmHg in Group I vs. from 93.0±10.0 to 82.0±7.5 mmHg in Group II (P>0.05 when compared two groups). Serum creatinine levels were reduced from 123.0±49.0 μmol/l to 85.4±30.6 μmol/l in Group I vs 116.8±51.2 μmol/l to 86.9±35.5 μmol/l (P<0.05 when compared two groups). Significantly reduction in MAU were noted in both groups (P<0.05) but when compared two groups there were no significant changes in reduction. Conclusion Renal artery stenting is effective method for the treatment of UHP and may improve outcomes of the patients. Bilateral stenting seems to be more effective in blood pressure and serum creatinine control in UHP.

Sign in / Sign up

Export Citation Format

Share Document